Loading...

RNA AVIDITY BIOSCIENCES INC Company Mergers 8-K Filing

VDTY

RN

AVIDITY BIOSCIENCES INC

(RNA)

2025 8-K

Summary

Summary

Merger Announcement

BLA Submission Update

Stock Offering Announcement

Stock Award Increase

Pre-Market Approval

Product Expansion

Earnings Releases

Office Expansion

Financial Results

Clinical Plans 2025

Cardiology Developments

Financial Results

Clinical Trial Update

FDA Approval Update

Earnings Reports

Investor Conferences

Annual Meeting Results

Underwriting Agreement

Amendment and Clinical Tria...

Appointment of Director

Earnings Reports

Investor Conferences

Private Placement

Resignation and Clinical Tr...

Clinical Trial Data

Bylaws Amendment

Agreement and Private Place...

Earnings Report

Clinical Study Data Present...

Earnings Reports

Annual Meeting Results

Clinical Hold Update

Earnings Reports

Presentation and Positive T...

Regulation FD Disclosure

Earnings Reports

Appointment of Directors an...

External Links:

On August 1, 2025, Avidity Biosciences, Inc. entered a seven-year manufacturing agreement with Lonza for producing drug substances, committing to purchase approximately $620 million worth in batches from 2026 to 2028. Additionally, they announced quarterly financial results on August 7, 2025.

AI Assistant

AVIDITY BIOSCIENCES INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.